Abbott Laboratories (ABT) Stock Analysis — Fair Value, Risk & Moat Rating
NYQ · Healthcare · Medical Devices
Is Abbott Laboratories a safe investment right now?
Abbott Laboratories's Altman Z-Score of 2.94 places it in the gray zone. Our DCF model estimates intrinsic value at $105.96, suggesting the stock may be undervalued by 9%. Moat rating: 2.4/5 stars.
Could Abbott Laboratories go bankrupt? Altman Z-Score analysis
Z-Score of 2.94 places the company in the gray zone (1.8-3.0), warranting closer scrutiny.
- Below 1.8 — Distress Zone (high bankruptcy risk)
- 1.8 to 3.0 — Gray Zone (elevated uncertainty)
- Above 3.0 — Safe Zone (financially healthy)
What drives ABT's Z-Score?
| Component | Formula | Value | Weight | Contribution |
|---|---|---|---|---|
| A · Working Capital / Total Assets | WC / TA | 0.1167 | 1.2 | 0.14 |
| B · Retained Earnings / Total Assets | RE / TA | 0.5805 | 1.4 | 0.81 |
| C · EBIT / Total Assets | EBIT / TA | 0.0796 | 3.3 | 0.26 |
| D · Market Cap / Total Liabilities | MCap / TL | 2.049 | 0.6 | 1.23 |
| E · Revenue / Total Assets | Rev / TA | 0.4927 | 1.0 | 0.49 |
How has ABT's financial health changed over time?
| Year | Z-Score | Zone |
|---|---|---|
| 2016 | 3.65 | Safe |
| 2017 | 3.58 | Safe |
| 2018 | 2.79 | Gray |
| 2019 | 2.46 | Gray |
| 2020 | 2.73 | Gray |
| 2021 | 2.7 | Gray |
| 2022 | 2.79 | Gray |
| 2023 | 3.12 | Safe |
| 2024 | 3.2 | Safe |
| 2025 | 2.94 | Gray |
Source: Calculated from ABT's latest 10-K filing on SEC EDGAR.
What is Abbott Laboratories actually worth?
Fair value range: $71.28 — $126.93
Valuation Methods
| Method | Fair Value | Weight | Detail |
|---|---|---|---|
| Historical PE × Forward EPS | $126.93 | 50% | 27.8x avg PE (4 years) × $4.57 forward EPS |
| DCF (Discounted Cash Flow) | $94.13 | 30% | Two-stage DCF: $7.2B TTM FCF, 6.9% growth, 8.2% WACC |
| EV/FCF Multiple | $71.28 | 20% | TTM FCF × 18x multiple + net cash |
Assumptions & Data Sources
| Parameter | Value | Source |
|---|---|---|
| FCF Growth Rate (Stage 1) | 6.9% | 70% analyst consensus + 30% historical |
| Analyst EPS Growth (This Year) | 6.4% | Consensus (25 analysts) |
| Analyst EPS Growth (Next Year) | 10.6% | Consensus |
| Historical 5Y FCF CAGR | 3.0% | SEC EDGAR |
| Terminal Growth Rate | 2.5% | Long-term GDP proxy |
| Discount Rate (WACC) | 8.2% | CAPM (Rf=4.3% + 0.78*5.5%) |
| Net Cash / (Debt) | $-5,197M | Balance sheet |
| Base FCF (TTM) | $7.2B | Historical avg |
| Shares Outstanding | 1,737,674,869 | Latest |
Sensitivity Analysis
| Growth Rate | 8% WACC | 10% WACC | 8.2% WACC | 13% WACC |
|---|---|---|---|---|
| 0% | $66.43 | $49.09 | $64.15 | $35.42 |
| 2.5% | $76.90 | $56.39 | $74.20 | $40.28 |
| 5.0% | $88.92 | $64.74 | $85.74 | $45.81 |
| 7.5% | $105.32 | $75.95 | $101.44 | $53.05 |
Free Cash Flow History
| Year | FCF | Growth |
|---|---|---|
| 2016 | $2.6B | — |
| 2017 | $1.9B | +-28.6% |
| 2018 | $2.1B | +12.2% |
| 2019 | $4.4B | +113.0% |
| 2020 | $4.9B | +10.6% |
| 2021 | $4.5B | +-8.3% |
| 2022 | $5.7B | +27.3% |
| 2023 | $8.6B | +51.1% |
| 2024 | $7.8B | +-9.8% |
| 2025 | $5.1B | +-35.2% |
Source: FCF data from SEC EDGAR filings. Price via Yahoo Finance.
Does Abbott Laboratories have a durable competitive advantage?
Moat rating: 2.4/5.
What makes up ABT's moat score?
ROIC Stability
ROIC variability over the past decade. Score: 3/5.
Gross Margin Trend
Gross margin trajectory over the past decade. Score: 3/5.
Switching Costs
Estimated customer lock-in based on margin level. Score: 1/5.
How stable is ABT's return on invested capital?
| Year | ROIC | Trend |
|---|---|---|
| 2016 | 8.1% | — |
| 2017 | 8.3% | Stable |
| 2018 | 6.9% | Declining |
| 2019 | 2.3% | Declining |
| 2020 | 6.5% | Rising |
| 2021 | 7.5% | Stable |
| 2022 | 8.6% | Rising |
| 2023 | 14.3% | Rising |
| 2024 | 14.1% | Stable |
| 2025 | 9.6% | Declining |
Source: ROIC calculated from SEC EDGAR filings.
Is Abbott Laboratories's dividend safe?
Can Abbott Laboratories afford its dividend?
Payout ratio is 67.2%. FCF covers the dividend 5.6x. 44 consecutive years of payments.
Abbott Laboratories's key financial metrics
| Metric | Latest | 1Y Ago | 3Y Ago | Trend |
|---|---|---|---|---|
| Revenue | $40.1B | $43.7B | $34.6B | Rising |
| Net Income | $5.7B | $6.9B | $4.5B | Rising |
| Free Cash Flow | $5.1B | $7.8B | $5.7B | Declining |
| Gross Margin | 13.7% | 13.2% | N/A | — |
Common questions about Abbott Laboratories
Is Abbott Laboratories at risk of going bankrupt?
Abbott Laboratories's Altman Z-Score of 2.94 places it in the gray zone. This metric uses balance sheet ratios to predict bankruptcy probability within 2 years. A score below 1.8 signals distress, while above 3.0 indicates safety.
What is Abbott Laboratories's intrinsic value based on DCF?
Our DCF model estimates Abbott Laboratories's intrinsic value at $105.96 per share. The current margin of safety is 9.4%. This estimate is based on historical free cash flow trends and a risk-adjusted discount rate.
Does Abbott Laboratories have a competitive moat?
Abbott Laboratories receives a moat rating of 2.4 out of 5 stars, based on ROIC stability, gross margin trends, and estimated switching costs. A rating above 3.5 suggests a durable competitive advantage.
Is Abbott Laboratories's dividend safe?
Our dividend safety analysis examines payout ratio, free cash flow coverage, and the company's streak of consecutive dividend payments to determine whether the current payout is sustainable.
Before you invest in Abbott Laboratories, make sure you truly understand it.
A deep understanding of a company's fundamentals, risk profile, and competitive position dramatically increases your investment accuracy and odds of success.
Pass the quiz to earn the ABT Certified Value Investor badge.
FairValueLabs Disclaimer
All valuations, scores, ratings, and classifications on this page are produced by the FairValueLabs internal valuation system. They do not represent actual market value, guaranteed outcomes, or professional investment advice. These are analytical estimates for educational and research purposes only.
This is not financial advice. All data is sourced from SEC EDGAR public filings. Always consult a qualified financial advisor before making investment decisions.
Last updated: Apr 20, 2026. Data sources: SEC EDGAR (financial statements), Yahoo Finance (market data, analyst consensus). Data may not reflect the most recent quarter.
ABT analysis methodology: How we calculate fair value, Z-Scores, and moat ratings